Pharmaceuticals
The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case
Let's look at the charts and indicators to round out the picture.
Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
Pfizer's Near-Term Correction Could Be Over
Pfizer may be done with its two-month correction but the uptrend may not resume right away.
The Technical Oracle of Delphi Says Merck Could Go Up or Down
How do the charts and indicators look ahead of their quarterly release?
Allergan Could Retest Its December Low Before a Better Rally Attempt
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
Shares of Abbott Laboratories Poised for Upside Breakout
ABT is pointed up after trading in a choppy range since October.
Two Sticking Points With Johnson & Johnson: Guidance and Litigation Expense
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Johnson & Johnson: How the Stock Looks on the Charts After Earnings
Experienced traders could approach the long side carefully.
My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout
The charts indicate that buyers of Aurinia have been more aggressive in recent weeks after a period of consolidation.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.